STUDY PROTOCOL

Study Protocol: Understanding SARS-CoV-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI) [version 1; peer review: 1 approved, 1 approved with reservations]

Maria Krutikov¹, Tom Palmer², Alasdair Donaldson³, Fabiana Lorencatto⁴, Gill Forbes⁴, Andrew J. Copas², James Robson⁵, Susan Hopkins⁶, Paul Moss⁷, Jeremy Farrar⁸, Andrew Hayward⁹, Laura Shallcross¹

¹Institute of Health Informatics, University College London, London, NW1 2DA, UK

²Institute for Global Health, University College London, London, WC1N 1EH, UK

³Department of Health & Social Care, UK Government, London, SW1H 0EU, UK

⁴Centre for Behaviour Change, University College London, London, UK

⁵Four Seasons Health Care, Wilmslow, Cheshire, SK9 1BU, UK

⁶National Infection Service, Public Health England, London, NW9 5EQ, UK

⁷Institute of Immunology & Immunotherapy, University of Birmingham, Birmingham, UK

⁸The Wellcome Trust, London, UK

⁹Institute of Epidemiology & Health Care, University College London, London, WC1E 7HB, UK

v1 First published: 07 Oct 2020, 5:232
<https://doi.org/10.12688/wellcomeopenres.16193.1>

Latest published: 29 Jan 2021, 5:232
<https://doi.org/10.12688/wellcomeopenres.16193.2>

Abstract

Global infection and mortality rates from severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are disproportionately high in certain populations, including the elderly. Care home residents are frequently exposed to infection due to contact with staff and other residents, and are highly susceptible to infection due to their age and co-morbidity. In England, official statistics suggest that at least 25% of all deaths in care home residents since the start of pandemic are linked to coronavirus disease 2019 (COVID-19), but limited testing for SARS-CoV-2 early in the pandemic means estimates of the true burden of disease are lacking. Additionally, little is known about patterns of transmission between care homes, the community and hospitals, or the relationship between infection and immunity in care home staff and residents. The VIVALDI study plans to address these questions.

VIVALDI is a prospective cohort study aiming to recruit 6,500 staff and 5000 residents from 105 care homes across England. Successive rounds of testing for infection will be performed over a period of 12 months. Nasopharyngeal swabs will detect evidence of viral RNA and therefore active infection (accompanied by collection of data on

Open Peer Review

Approval Status

	1	2
version 2		
(revision)
29 Jan 2021	view	view

version 1
07 Oct 2020	view	view

1. **Adam L Gordon**, University of Nottingham, Nottingham, UK

2. **Kanwar Hamza Shuja**¹, Quaid-I-Azam University, Islamabad, Pakistan
 Foundation University Rawalpindi Campus, Newlalazar, Pakistan

Any reports and responses or comments on the

symptoms), whereas blood tests will detect antibodies and evidence of cellular immunity to SARS-CoV-2. Whole genome sequencing of viral isolates to investigate pathways of transmission of infection is planned in collaboration with the COVID-19 Genomics UK Consortium. Qualitative interviews with care home staff will investigate the impact of the pandemic on ways of working and how test results influence infection control practices and behaviours. Data from residents and staff will be linked to national datasets on hospital admissions, antibody and PCR test results, mortality and care home characteristics.

Data generated will support national public health efforts to prevent transmission of COVID-19 and protect care home staff and residents from infection.

Protocol registration: [ISRCTN14447421](#) 05/06/2020

Keywords

COVID-19, care homes, epidemiology, transmission, antibody, immunity, ageing, PCR

This article is included in the [Coronavirus \(COVID-19\)](#) collection.

Corresponding author: Maria Krutikov (m.krutikov@ucl.ac.uk)

Author roles: **Krutikov M:** Investigation, Methodology, Project Administration, Writing – Original Draft Preparation; **Palmer T:** Data Curation, Methodology, Writing – Original Draft Preparation, Writing – Review & Editing; **Donaldson A:** Conceptualization, Funding Acquisition; **Lorencatto F:** Conceptualization, Investigation, Methodology, Writing – Review & Editing; **Forbes G:** Conceptualization, Investigation, Methodology; **Copas AJ:** Data Curation, Methodology, Writing – Review & Editing; **Robson J:** Project Administration; **Hopkins S:** Conceptualization, Funding Acquisition; **Moss P:** Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision; **Farrar J:** Conceptualization, Funding Acquisition, Supervision; **Hayward A:** Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision; **Shallcross L:** Conceptualization, Funding Acquisition, Investigation, Methodology, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing

Competing interests: No competing interests were disclosed.

Grant information: The study is supported by funding from the Department of Health & Social Care, UK government. LS holds a NIHR Grant [CS-2016-16-007]. JF is the Director of the Wellcome Trust.

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

Copyright: © 2020 Krutikov M *et al.* This is an open access article distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite this article: Krutikov M, Palmer T, Donaldson A *et al.* **Study Protocol: Understanding SARS-Cov-2 infection, immunity and its duration in care home residents and staff in England (VIVALDI) [version 1; peer review: 1 approved, 1 approved with reservations]** Wellcome Open Research 2020, 5:232 <https://doi.org/10.12688/wellcomeopenres.16193.1>

First published: 07 Oct 2020, 5:232 <https://doi.org/10.12688/wellcomeopenres.16193.1>

article can be found at the end of the article.

Introduction

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has caused a large number of deaths worldwide and rapidly changed how people live their lives by restricting social contact and daily activities. Early evidence pointed to the disproportionate impact of coronavirus disease 2019 (COVID-19) on the elderly, ethnic minorities and people with co-morbidities^{1,2}. Care home residents have underlying risk factors for severe outcomes (age, comorbidity), but are also likely to have high rates of exposure to infection, through contact with care home staff or other residents. Studies from the USA, Canada and Europe have consistently shown high prevalence of SARS-CoV-2 in care home residents and staff, associated with significant mortality in residents^{3–5}.

In England an estimated 450,000 individuals aged > 65 years live in approximately 9,000 care homes⁶. Mortality data from the Office of National Statistics (ONS) suggests that >45,000 care home residents have died during the pandemic, although only 12,500 of these deaths were explicitly linked to COVID-19⁷. Accurate estimates of the burden of SARS-CoV-2 infection in care home residents and staff and the proportion of cases without symptoms are lacking because there has to date been limited testing for infection (antibody and RNA tests), and there is no comprehensive surveillance system for infection in care homes. We also have little insight into how infection transmits in the care home, both between staff and residents, and between care homes and other settings (community, hospitals), or how the pandemic has impacted on ways of working in the care home. The prevalence and duration of immunity to SARS-CoV-2 among staff and residents is also unknown.

The Department of Health & Social Care is currently rolling out infection (PCR) testing to all care home staff and residents⁸. This will provide accurate data on the prevalence of infection across all care homes and insights into the types of care homes that are most likely to develop outbreaks. But this large-scale approach is not well-suited to assessing how outbreaks progress over time, or duration of immunity – information that is essential to inform the approach to testing in care homes for current and future pandemic waves.

These questions can be answered most efficiently through a large prospective cohort study of care home staff and residents with repeat testing for infection and analysis of the immune response (antibody and cellular immunity). This will be combined with detailed data collection on symptoms and risk factors for infection, and linkage to NHS and public health data sources including viral sequencing. Through linkage to an existing study ([CATCH-19](#)), we will also undertake qualitative interviews with 30 healthcare workers in a subset of care homes to gain insights into how the pandemic has impacted on healthcare staff and ways of working in the care home. This study is one of the largest undertaken in care homes, and will inform planning and the national public health response to COVID-19

This VIVALDI-2 study will be performed in conjunction with the VIVALDI-1 study. VIVALDI-1 is a cross-sectional survey of all 9000 care homes in England which provide dementia care or care to residents aged >65 years. The study is a

collaboration between the ONS, Public Health England and UCL. The survey was delivered to care home managers and collected information on care home characteristics and staffing (number and type of staff, number of residents, sickness pay, use of agency staff), disease control measures (cohorting, isolation, care home closures) and cases of infection in staff and residents. Care home level responses will be linked to individual-level PCR results from the national surveillance whole care home testing data and analysed. Results from the survey are publicly available on the ONS website and have informed government policy on COVID-19 testing in care homes⁹.

Methods

Study design

Prospective cohort study

Settings

105 care homes in England run by the Four Seasons Health Care (FSHC) group.

Participants

Inclusion criteria. All residents aged > 65 years and all staff at participating FSHC care home sites; estimated as 11,500 potential participants (5,000 residents and 6,500 staff).

Exclusion criteria. Individuals with capacity who have insufficient reading comprehension to understand the consent materials.

Study schedule

Baseline assessments and blood sampling (antibody testing and cellular immunity). Demographic data and dates of care home entry and exit will be extracted from FSHC systems for all residents and healthcare staff. We will also extract information on care home characteristics (number of beds, residential and nursing care beds, number of patients with dementia, numbers of staff and type, staff turnover, care quality commission (CQC) rating, region, physical layout of the care home, number of visitors, number of suspected and confirmed SARS-CoV-2 cases, number of hospital admissions and deaths).

Blood samples will be performed for baseline testing of antibody response and cellular immunity in all consenting staff and residents; and from residents who lack capacity provided there is strong justification for this (see section on consent).

Intensive testing for infection (PCR, antibody testing and cellular immunity) and duration of the antibody and cellular immune response. All participants will undergo testing with nasopharyngeal swabs to detect SARS-CoV-2 viral RNA using PCR testing and blood testing to detect antibodies to this virus and cellular immunity. Two further rounds of PCR testing will be repeated at 7–28 day intervals with accompanying symptom data capture. Homes found to have active outbreaks will be prioritised for repeat testing earlier in this window.

Saliva will be collected alongside nasopharyngeal swabs in staff and residents in a subset of 4–8 care homes for PCR testing, to assess saliva as a diagnostic sample type.

Further rounds of blood sampling will be repeated at 6 weeks and 3 months in all participants and at 6 and 12 months in a subset of residents to assess the duration of the antibody response and whether cellular immunity wanes over time.

Laboratory procedures

Laboratory tests will not be performed by the study team but will be contracted to external laboratories performing these tests as part of their current workload.

All PCR will be performed in national laboratories as part of the national testing programme on clinical isolates from nasopharyngeal swabs. Nasopharyngeal swabs will be carried out by trained care home staff or self-taken according to written instructions. These will be couriered on the same day to the central laboratory who will store them for testing.

PCR testing is performed using an Applied Biosystems 7500 Fast real time PCR system and using the Applied Biosystems TaqPath™ 1-Step Multiplex Master Mix (No ROX) (Cat. A28523) and TaqPath COVID-19-ASY-KIT 1000 (Cat. A47817). Primer sequence details are not currently published. Real time PCR cycling occurs as described in the Applied Biosystems guidelines and involves 1 cycle for 2 minutes at 25°C, 1 cycle for 10 minutes at 53°C, 1 cycle for 2 minutes at 95°C and then 40 cycles of 3 seconds at 95°C and 30 seconds at 60°C. A positive extraction control (Qnostics SARS-CoV-2 Positive Control cat. SCV2PC-075) and negative extraction control (RNase-free water) is included in each plate. Quantification of the Positive/Negative/Inconclusive status of each sample is determined using the [UgenTec FastFinder](#) Interpretative software.

Blood samples will be collected by trained phlebotomists and will be couriered on the same day to the relevant laboratories for testing and storage.

Antibody tests will be performed using the Abbott *in vitro* SARS-CoV-2 IgG 6R86 assay using the ARCHITECT diagnostic platform which is widely used across NHS hospitals. These will be carried out in a commercial laboratory who will be contracted by the study team.

Tests of cellular immunity will be performed on collected blood samples by the University of Birmingham study team using a separate protocol and ethics approval, which will be added to the data repository after it has been finalised.

Data linkage

We will undertake quarterly data linkage to Hospital Episodes Statistics, Mortality data and virological test results from March 1st 2020 onwards for all care home residents and staff. The legal basis for accessing identifiable data from all staff and residents without consent is provided through Covid-19: Notice under Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002 (COPPI)¹⁰. Data linkage will continue for a period of up to 2 years as we anticipate that there will be additional waves of the pandemic in subsequent years.

Whole genome sequencing

We will collaborate with the COVID-19 Genomics UK Consortium (COG-UK) to sequence viral samples derived from nasopharyngeal swabs from care home staff and residents and link results to epidemiological information (symptoms, dates of infection, admission to hospital, geographical location and care home layout). Sequencing data from care home residents and staff will be compared to sequences derived from hospitals and the community in the region surrounding each care home to make inferences about how SARS-CoV-2 spreads between care homes, the community and hospital settings. We will also explore patterns of transmission within the care home, and whether this varies dependent on whether the index case, as determined by mutations within the sequences and epidemiological data, was symptomatic or asymptomatic, or a member of staff or resident. We will also explore how care home factors such as building layout influence transmission of infection in the care home.

Qualitative interviews with care home staff

We will undertake in-depth, semi-structured qualitative interviews with 30 care home staff from a sub-sample of participating care homes. This will be done through collaboration with an existing UCL-led study entitled *COVID-19 Impact and Burden in Care Homes (CATCH-19)*, which is funded by the Economic and Social Research Council (ESRC) [ES/V003887/1]. FSHC will identify 6–8 potential care homes for inclusion in this sub-study, considering factors such as care home size, region and the number of COVID-19 cases reported by the care home.

We will use purposive, maximum variation sampling to recruit 3–5 participants per care home, from a range of staff roles (e.g. managers, care assistants, nurses). Interviews will be conducted in the months following the introduction of serological testing (months 2–5 of the study) and will explore the different ways in which the pandemic has impacted on care home staff, residents and ways of working, including: management of suspected or confirmed COVID-19 cases, interaction with other healthcare professionals and settings (e.g. primary and secondary care), access to medicines, advanced care planning, impact on non-COVID-19 care, and staff well-being. The interviews will also focus on how staff interpret and respond to PCR and antibody test results, as well as the subsequent impact on infection prevention control practices and staff behaviours. Specifically, the extent to which care home staff enact personal protective behaviours (i.e. use of PPE, social distancing in the work place)¹¹ and the barriers and enablers to these behaviours. The protocol and topic guide for the qualitative interviews have already been granted ethical approval by the UCL Research Ethics Committee (UCL REC ref: 13355/002) so details are not included in this protocol.

Data sources / measurement

The study will include primary data collection, extraction of information from electronic administrative data and linkage to existing medical records. Primary data collection will include nasopharyngeal swabs and saliva for PCR testing; blood samples

for antibody testing and storage for analysis of the cellular immune response; data on symptoms of infection to accompany PCR testing; recording of ethnicity; information on care home characteristics and risk factors for infection such as the number of visitors; qualitative interview data.

Data will be extracted from care home records to find out the number of COVID-19 cases, hospital admissions and deaths by care home dating back to March 1st 2020. Individual-level data will also be extracted for care home residents (age, gender, dates of entry and exit to and from the care home) and for care home staff (dates they started/stopped working at the care home).

A brief symptom questionnaire will be performed at the time of nasopharyngeal sampling and for the subsequent 7 days to ascertain presence and development of symptoms. This will be performed by the care home manager. The questionnaire is available in the UCL Data Repository (extended data¹²).

Data linkage will be undertaken in the [NHS Foundry](#) and overseen and quality assured by NHS England. [Figure 1](#) outlines the data flow for the study.

Sample size

Assuming that around 80% of eligible staff and residents will participate, then on average approximately 38 residents and 49 staff will be tested per home across the 105 homes. Based on a conservatively estimated intra-cluster correlation of 0.36 (twice that reported for seasonal influenza¹³) leads to effective sample sizes of around 279 residents and 285 staff, after accounting for the loss of precision due to clustering. Assuming an antibody prevalence of around 30% for both groups the precision of the estimate (based on 95% confidence interval width) will be $\pm 5.4\%$ for residents and for staff separately.

Importantly, as we anticipate that at least 1000 residents will have been infected at 3 months (using a conservative estimate of 20% infection prevalence), we should have sufficient precision and power to detect changes in antibody prevalence over time. For example, assuming 80% of infected residents agree to repeated antibody testing and 70% of these have an antibody response at 3 months (560 residents) then we can estimate the proportion of these retaining a response at 6 months within 4.2% assuming a retention rate of 50%. This assumes that antibody response is broadly unaffected by care home level factors.

Outcomes

Primary outcome. The proportion of staff and residents who have previously been infected with SARS-CoV-2 based on presence of antibodies in serum at baseline, 6 weeks and 3 months.

Secondary outcomes

- The incidence and prevalence of acute infection and asymptomatic infection, at each round of swab testing

- The proportion of residents and staff with a new antibody response to SARS-CoV-2 at 3 months
- The proportion of residents with an antibody response to SARS-CoV-2 at 6 and 12 months, to investigate the duration of antibody response in this population
- The distribution of quantitative IgG and IgM responses to SARS-CoV-2 amongst staff and residents.
- Estimate the direct and indirect mortality in care home residents attributable to SARS-CoV-2
- Investigate transmission of SARS-CoV-2 between care homes, hospitals and the community by linking viral whole genome sequencing data from care home staff and residents to epidemiological information, and comparing sequences from the care home population to sequences that are circulating in local hospitals and the community
- Compare disease incidence, seroprevalence and symptom profiles, in care home residents and the general population
- Evaluate the performance of PCR to detect infection using saliva versus nasopharyngeal swabs
- Model the risk of importation of infection to care homes following discharge of a resident from hospital by linking to data on hospital admissions
- Use qualitative interviews to investigate the impact of the pandemic on ways of working in the care home, infection prevention control practices and behaviours, and to investigate how care home staff are interpreting and using Covid-19 test results.

Data analysis and statistical analysis plan

A formal statistical analysis plan has been developed and can be accessed in the UCL data repository (extended data¹⁴) and a summary is presented here. All data analysis will be performed using [Stata](#) version 15.

The sample proportions of staff and residents will be presented as summary statistics for the primary outcomes, together with the proportion of care homes with any antibody detection. Univariate logistic regression modelling with random effects for care home will identify risk factors for the primary outcome which will subsequently be included in a multiple regression model.

The rates of antibody acquisition, hospital admission and mortality will be presented. Duration of antibody response will be described by a Kaplan-Meier curve. Appropriate regression modelling will be performed to establish risk factors and associated variables with each outcome and will be presented as hazard, odds or rate ratios. Associations with loss of antibody response and risk of death will be investigated using Cox regression

1	Lists of residents (names) and symptoms collected with each round of swabbing
2	Blood sampling of residents and staff
3	Saliva samples collected from a subset of residents and staff
4	Nasopharyngeal swabs collected from residents and staff
5	Nasopharyngeal swabs sent to National Biosample Centre for PCR testing
6*	Test results returned to Foundry and to participants
7*	Blood test results sent to Foundry and to participants
8	Validation test result returned from Oxford Lab to the Foundry
9	Salivary test results returned from Crick to the Foundry
10	Results from cellular immune analyses returned to Foundry
11	FSHC data manager collates resident lists and sends them to the Foundry
12	NHS Digital datasets shared with the Foundry (HES, ONS) for data linkage
13	PHE testing datasets shared with the Foundry for data linkages
14	Healthcare Providers care home data shared with the Foundry for linkage
15	Dataset pseudo-anonymised and shared with UCL research team
*	Return of results to patients/care homes via existing reporting mechanisms

PCR Polymerase Chain Reaction
HES Hospital Episode Statistics
UCL University College London
HCP Healthcare Providers

FSHC four Seasons Health Care
ONS Office for National Statistics
NHS-D NHS-Digital

NHS National Health Service
PHE Public Health England
DSH Data Safe Haven

Figure 1. Data flows to enable safe, secure transfer of patient identifiable data and linkage.

models. Poisson regression modelling will be conducted to investigate risk factors for new antibody development during study period and for hospital admissions.

All analyses will be conducted separately for staff and residents. The detailed statistical analysis plan will include a methodology to handle missing testing data.

The plan for analysis of viral sequencing data has not yet been developed. The topic guide and analysis plan for the qualitative interviews is described in the CATCH-19 protocol available in the UCL data repository (extended data¹⁵).

Consent

Informed consent to participate will be collected in writing from all care home staff. Wherever possible, written informed consent will be sought directly from residents. Study information materials will be translated into other languages upon request.

For residents who lack capacity, the care home will contact a friend or next of kin to act as personal consultee. If a personal consultee cannot be identified, a nominated consultee, such as the care home manager or a member of staff will be asked to complete a professional declaration form. This approach meets the four criteria for HRA approval as set out in sections 31–33 of the Mental Capacity Act 2005¹⁶. This approach is also justified by the current lack of research in this population that can address important questions regarding impact and transmission of COVID-19.

Data sharing

Research outputs will be published in open access journals and analytical code will be made available. A de-identified copy of the dataset will be made available for future research, however, decisions around the details shared will be made in partnership with FSHC. Fully anonymised transcripts from qualitative interviews will be archived in the [UCL Research Data Repository](#), where they will be made accessible to other researchers.

Ethics

The study has been approved by the South Central - Hampshire B Research Ethics Committee (reference number 20/SC/0238).

Dissemination

Rapid results from this study will be shared with national advisory committees and organisations who are leading the pandemic response. Results will also be shared with Four Seasons Health Care and participants. Planned publication in a high impact peer-reviewed journal within one year of study end date.

Study status

At the time of protocol submission, all participating sites had been identified and recruitment had started.

This study has been registered with ISCRTN under registration number [14447421](#) on the 5th June 2020.

Data availability

Underlying data

No data are associated with this article.

Extended data

UCL Data Repository: COVID-19 in care homes study (VIVALDI) - Symptom questionnaire.xlsx. <https://doi.org/10.5522/04/12764441.v1>¹²

- Symptom record V2 070720.xlsx (Symptom questionnaire administered to all study participants on the day of nasopharyngeal swab (SARS-CoV-2 PCR) that assesses for evidence of current infection)

UCL Data Repository: COVID-19 in care homes (VIVALDI) Statistical analysis plan. <https://doi.org/10.5522/04/12821633.v1>¹⁴

- VIVALDI analysis plan v1.2 final.pdf (Data analysis plan for VIVALDI-2 study performed by UCL researchers in 105 Four Seasons care homes across England)

UCL Data Repository: CATCH-19 topic guide. <https://doi.org/10.5522/04/12821663.v1>¹⁵

- CATCH-19_topic_guide_V2_02.06.20.docx (Topic guide for CATCH-19 study qualitative interviews to be held with care home staff that are taking part in the VIVALDI study)

Data are available under the terms of the [Creative Commons Attribution 4.0 International license](#) (CC-BY 4.0).

Acknowledgements

The study team would like to acknowledge the role of Four Seasons care home staff, residents and personal consultees in delivering this study.

References

1. Zhou F, Yu T, Du R, *et al.*: **Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study.** *Lancet.* 2020; **395**(10229): 1054–1062. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
2. Aldridge RW, Lewer D, Katikireddi SV, *et al.*: **Black, Asian and Minority Ethnic groups in England are at increased risk of death from COVID-19: indirect standardisation of NHS mortality data [version 2; peer review: 3 approved].** *Wellcome Open Res.* 2020; **5**: 88. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
3. McMichael TM, Currie DW, Clark S, *et al.*: **Epidemiology of Covid-19 in a Long-Term Care Facility in King County, Washington.** *N Engl J Med.* 2020; **382**(21): 2005–2011. [PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
4. Observer Reporters: **Across the world, figures reveal horrific toll of care**

home deaths. *The Guardian*.

[Reference Source](#)

5. Fisman D, Lapointe-Shaw L, Bogoch I, *et al.*: **Failing our Most Vulnerable: COVID-19 and Long-Term Care Facilities in Ontario.** *medRxiv*. 2020.
[Publisher Full Text](#)
6. LaingBuisson: **Care homes for older people UK market report.** 2019.
[Reference Source](#)
7. Office for National Statistics: **Deaths involving COVID-19 in the care sector, England and Wales: deaths occurring up to 1 May 2020 and registered up to 9 May 2020 (provisional).** 2020.
[Reference Source](#)
8. Department of Health & Social Care: **Coronavirus (COVID-19) Scaling up our testing programme.** 2020.
[Reference Source](#)
9. Office for National Statistics, University College London, Department of Health & Social Care, Public Health England & Ipsos Mori: **Impact of coronavirus in care homes in England: 26 May to 19 June 2020.** 2020.
[Reference Source](#)
10. Department of Health & Social Care: **Covid-19 – Notice under Regulation 3(4) of the Health Service Control of Patient Information Regulations 2002.** 2020.
[Reference Source](#)
11. West R, Michie S, Rubin GJ, *et al.*: **Applying principles of behaviour change to reduce SARS-CoV-2 transmission.** *Nat Hum Behav.* 2020; **4**(5): 451–459.
[PubMed Abstract](#) | [Publisher Full Text](#)
12. Krutikov M, Shallcross L, Copas A, *et al.*: **COVID-19 in care homes study (VIVALDI) - Symptom questionnaire.xlsx.** University College London. Workflow. 2020.
<http://www.doi.org/10.5522/04/12764441.v1>
13. Hayward AC, Fragaszy EB, Bermingham A, *et al.*: **Comparative community burden and severity of seasonal and pandemic influenza: Results of the Flu Watch cohort study.** *Lancet Respir Med.* 2014; **2**(6): 445–54.
[PubMed Abstract](#) | [Publisher Full Text](#) | [Free Full Text](#)
14. Krutikov M, Palmer T, Copas A, *et al.*: **COVID-19 in care homes (VIVALDI) Statistical analysis plan.** University College London. Data management plan. 2020.
<http://www.doi.org/10.5522/04/12821633.v1>
15. Krutikov M, Lorencatto F, Forbes G, *et al.*: **CATCH-19 topic guide.** University College London. Workflow. 2020.
<http://www.doi.org/10.5522/04/12821663.v1>
16. Department for Constitutional Affairs: **Mental Capacity Act 2005.** Section 31-33 (Department for Constitutional Affairs). 2005.
[Reference Source](#)

Open Peer Review

Current Peer Review Status: ? ✓

Version 1

Reviewer Report 19 January 2021

<https://doi.org/10.21956/wellcomeopenres.17781.r41974>

© 2021 Shuja K. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Kanwar Hamza Shuja

¹ National Institute of Psychology (NIP), Quaid-I-Azam University, Islamabad, Pakistan

² Foundation University Rawalpindi Campus, Newlalazar, Rawalpindi Cantt, Pakistan

The article is a proposal of sort as it has proposed a plan for conducting a study using a cohort method. The introduction is written with a clear focus, explaining all the important points as it should, though, from the perspective of a layman, the authors should explain a little bit about what a VIVALDI cohort study is as it's not much even discussed in the method section. The rest of the method section though is written very scientifically and all the measures have clearly been explained. Since it is a longitudinal study there is no current data set present with this article as it is only proposing or laying out a plan for the study. This can be useful as the authors have written steps very detailed which can be used for replication purposes by other countries to assess the settings where COVID-19 is most prevalent. Overall the study in its current form has not added anything new but can be a useful article for the purpose of replication and in its follow-up studies depending upon how long the COVID-19 virus remains.

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Not applicable

Competing Interests: No competing interests were disclosed.

Reviewer Expertise: Clinical psychology, criminal psychology, forensic psychology.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

Author Response 26 Jan 2021

Maria Krutikov, University College London, London, UK

We thank you for your review and evaluation of this manuscript.

Competing Interests: No competing interests were disclosed.

Reviewer Report 18 January 2021

<https://doi.org/10.21956/wellcomeopenres.17781.r41770>

© 2021 Gordon A. This is an open access peer review report distributed under the terms of the [Creative Commons Attribution License](#), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Adam L Gordon

Division of Rehabilitation & Ageing, University of Nottingham, Nottingham, UK

I found this a relatively straightforward and easy to follow protocol and I have only a couple of minor pointers.

The authors use the word “elderly”, which PPI groups for older people consistently tell us is not acceptable. The widely accepted term is “older people”.

I was initially left confused about whether people who lack mental capacity to provide consent would be included. I eventually decided that they must be, because there is a section at the bottom that talks about consultee procedures for residents who lack capacity. Under inclusion and exclusion criteria the authors mention those who have capacity but don't have the reading aptitude to engage with the study materials. But they don't make an explicit statement about those who lack capacity. I would prefer to see them make a clear statement about inclusion of those who “lack capacity and have an available consultee”. As the authors have chosen to include care home staff as eligible consultees (ethics committees will have a variable opinion on this – but my guess is that they may have successfully used this approach during Vivaldi-I) then it's likely that most people without capacity will be eligible for inclusion. An explicit statement would be helpful.”

Is the rationale for, and objectives of, the study clearly described?

Yes

Is the study design appropriate for the research question?

Yes

Are sufficient details of the methods provided to allow replication by others?

Yes

Are the datasets clearly presented in a useable and accessible format?

Yes

Competing Interests: No competing interests were disclosed.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

Author Response 26 Jan 2021

Maria Krutikov, University College London, London, UK

We thank you for your comments which we have addressed below:

1. Thank you for bringing our attention to the more widely accepted terminology. We have changed the terms "elderly" to "older people" throughout the manuscript.
2. In order to clarify that we are including people with a consultee who lack the capacity to consent, we have added a statement that outlines this under the inclusion criteria section. We have also added in a clarification that people will not be excluded if they cannot speak English as we will translate study materials as necessary.

Competing Interests: No competing interests were disclosed.